TOKYO, May 28, 2025 - (JCN Newswire) - - Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in ...

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with ...

Tsukuba, Japan—Orexin, named after its role in feeding regulation, is a potent endogenous sleep/wake state regulator and is expected to play an essential role in controlling the cross-talk mechanism ...

What exactly happens in our brain when we make the decision about whether to exercise, or whether to reach for a particularly tempting snack, has to date been a mystery to science. Studies in mice by ...